Delivery Order SPE2DB20D3101-SPE2DB23FRVN7
- Not listed
- This federal contract award is for the delivery of Lacosamide 10 mg/ml solution (200 ml) to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,657.44 and a completion date of December 14, 2023. It is a firm fixed-price delivery order contract, with no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora,...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,565.03 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Lacosamide 10 mg/ml solution in 200 ml vials. This order is part of a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025, to deliver a comprehensive range of pharmaceuticals and medical supplies to support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,381.20, is for the delivery of Lacosamide 10 mg/ml solution in 200 ml containers. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4563830313 - Lacosamide 10 mg/ml solution 200 ml. The contract has a completion date of March 4, 2024 and a potential value of $1,450.26. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation for this award. The contract is part of a larger indefinite delivery contract (IDC) between...
- This federal contract award, valued at $1,254.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The award is for the delivery of Lacosamide 10 mg/ml Solution 200 ml, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of September 23, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 between Amerisourcebergen and the DLA...
- This federal contract award, valued at $3,996.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of Lacosamide 10 mg/ml solution, a pharmaceutical product. It has an ultimate completion date of December 27, 2024. The contract is a Firm Fixed Price arrangement and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $1,072.37 for the supply of Lacosamide 10 mg/ml solution. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of November 22, 2024. The contract is a Firm Fixed Price arrangement and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Lacosamide 10 mg/ml solution in 200ml containers. The $3,211.44 contract has a completion date of January 23, 2024. Amerisourcebergen Drug Corp, as the prime contractor, will deliver the pharmaceutical product from its corporate office location in Conshohocken, Pennsylvania. This award is not associated with a set-aside program....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,747.54 firm fixed-price delivery order is for the supply of Lacosamide 10 mg/ml solution in 200 ml vials. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 through December 2025, which enables DLA Troop Support Medical to efficiently procure a comprehensive range of medical commodities to support...
- This federal contract award to Amerisourcebergen Drug Corporation's Corporate Office Division is for the delivery of 4565662476 Lacosamide 10 mg/ml solution in 200 ml containers. The contract has a ceiling value of $1,013.31 and is a Delivery Order placed by the Defense Logistics Agency (DLA), a defense agency. The contract is a Firm Fixed Price arrangement with no set-aside designation. It has an ultimate completion date of September 4, 2024. Amerisourcebergen, one of the largest pharmaceutical...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FRVN7Delivery Order
This federal contract award is for the delivery of Lacosamide 10 mg/ml solution in 200 ml vials to the Defense Logistics Agency (DLA). The contract, valued at $1,381.20, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on August 22, 2023. The contract has a completion date of August 23, 2023 and is a firm fixed-price delivery order. There is no set-aside designation for this award. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization registered in the System for Award Management (SAM.gov). The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/22/23 |